| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
Hexakis(p-bromophenoxy)cyclotriphosphazene has been found to act as an inhibitor of the activation of ion channels by G proteins, binding to the receptor and blocking its ability to bind G proteins. This mechanism involves direct interaction with G protein-coupled receptors to prevent G protein activation and subsequent ion channel opening. The compound's unique architecture allows for selective interactions with protein targets. As a cyclophosphazene, it can also serve as a metal-organic framework with significant potential for gas capture and storage applications due to its high surface area and tunable pore structure. The compound's biological activity is attributed to its ability to interact with proteins and cellular membranes.
|
|---|---|
| ln Vitro |
In vitro, hexakis(p-bromophenoxy)cyclotriphosphazene has been studied for its effects on ion channel function and protein interactions. The compound inhibits the activation of ion channels by G proteins, demonstrating its ability to interfere with G protein-coupled receptor signaling. Binding studies have shown that the compound binds to receptors and blocks their ability to bind G proteins. This mechanism of action makes it a valuable tool for studying G protein-coupled receptor signaling and ion channel regulation. The compound's effects on cellular function depend on the specific receptors and cell types being studied. Its activity as a metal-organic framework for gas capture has also been characterized in materials science applications.
|
| ln Vivo |
In vivo studies of hexakis(p-bromophenoxy)cyclotriphosphazene are limited, as the compound is primarily used as a chemical reagent and materials science tool rather than a therapeutic agent. The compound's biological activity as an inhibitor of G protein-mediated ion channel activation suggests potential applications in studying receptor signaling in animal models. However, detailed in vivo efficacy and safety data are not extensively documented. The compound's use as a flame retardant and polymer additive indicates that its biological effects may be relevant for toxicological assessments in the context of material safety and environmental exposure. Further research is needed to fully characterize its in vivo biological activity.
|
| Enzyme Assay |
For in vitro biochemical assays, hexakis(p-bromophenoxy)cyclotriphosphazene can be evaluated for its interactions with proteins and receptors. Binding assays can be performed using purified G proteins or G protein-coupled receptors to assess direct compound-protein interactions. Techniques such as surface plasmon resonance (SPR), isothermal titration calorimetry (ITC), or fluorescence polarization can be used to measure binding affinity. Ion channel function can be assessed using electrophysiological techniques in cell-free systems. The compound's ability to inhibit G protein activation can be measured using GTPase activity assays or nucleotide exchange assays. These cell-free assays help characterize the molecular mechanism of action and identify the specific protein targets of the compound.
|
| Cell Assay |
In vitro cellular assays for hexakis(p-bromophenoxy)cyclotriphosphazene can be performed using cells expressing G protein-coupled receptors and ion channels. Cells are cultured in standard media and treated with the compound at various concentrations. G protein activation is assessed by measuring GTPγS binding or downstream signaling events such as cAMP production, calcium mobilization, or MAPK activation. Ion channel activity is measured using patch-clamp electrophysiology or fluorescence-based membrane potential assays. Cell viability and cytotoxicity are assessed using MTT or LDH release assays. Receptor binding studies using radiolabeled ligands can determine the compound's affinity and selectivity for specific receptor subtypes. These cellular assays help validate the compound's mechanism of action in a physiologically relevant context.
|
| Animal Protocol |
In vivo animal experiments with hexakis(p-bromophenoxy)cyclotriphosphazene are not extensively documented in the literature. As a chemical reagent and materials science compound, it is primarily used in non-biological applications. If used in animal studies, typical approaches would involve administration via oral gavage, intraperitoneal injection, or intravenous injection. Dosing regimens would be determined based on the compound's pharmacokinetic properties and tolerability. Endpoint analyses would depend on the specific biological question being addressed, such as assessment of receptor signaling, ion channel function, or toxicological effects. Researchers should consult the primary literature for any available in vivo data.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of hexakis(p-bromophenoxy)cyclotriphosphazene are not extensively documented. As a cyclophosphazene compound with multiple bromophenoxy groups, it is expected to have high molecular weight and lipophilicity. These properties suggest low oral bioavailability and limited systemic distribution. The compound is likely to be metabolized in the liver and eliminated via biliary or renal routes. Its use as a flame retardant additive and polymer component suggests that its pharmacokinetic properties are more relevant for environmental and toxicological studies than for therapeutic applications. Detailed PK parameters such as half-life, Cmax, Tmax, and AUC are not available in the literature.
|
| Toxicity/Toxicokinetics |
The toxicological profile of hexakis(p-bromophenoxy)cyclotriphosphazene has been studied primarily in the context of its use as a flame retardant and industrial chemical. As a halogenated compound containing bromine atoms, it may have potential for bioaccumulation and toxicity. Comprehensive toxicity assessments would include acute, subchronic, and chronic toxicity studies in animal models. Parameters assessed would include body weight, organ weights, hematology, clinical chemistry, and histopathology. Genotoxicity and carcinogenicity potential would also be evaluated. The compound's environmental persistence and ecotoxicological effects are relevant considerations for its industrial applications. The compound is intended for research and industrial use only and not for human therapeutic applications.
|
| Additional Infomation |
Hexakis(p-bromophenoxy)cyclotriphosphazene is primarily a chemical reagent and materials science compound with diverse applications. It is used in research as a tool for studying ion channels and protein interactions. Its ability to inhibit G protein-mediated ion channel activation makes it valuable for investigating GPCR signaling mechanisms. In materials science, the compound is used for polymer functionalization, as a flame retardant additive, and as a building block for metal-organic frameworks with gas capture applications. Its unique cyclotriphosphazene core with six p-bromophenoxy groups provides opportunities for studying structure-function relationships in both biological and materials contexts. The compound is also relevant for environmental and toxicological research due to its use as an industrial chemical.
|
| Molecular Formula |
C36H24BR6N3O6P3
|
|---|---|
| Molecular Weight |
1166.9375
|
| Exact Mass |
1160.6
|
| Elemental Analysis |
C, 37.05; H, 2.07; Br, 41.08; N, 3.60; O, 8.23; P, 7.96
|
| CAS # |
4376-72-1
|
| PubChem CID |
4261415
|
| Appearance |
Solid powder
|
| LogP |
15.194
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
54
|
| Complexity |
1090
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
BrC1C([H])=C([H])C(=C([H])C=1[H])OP1(N=P(N=P(N=1)(OC1C([H])=C([H])C(=C([H])C=1[H])Br)OC1C([H])=C([H])C(=C([H])C=1[H])Br)(OC1C([H])=C([H])C(=C([H])C=1[H])Br)OC1C([H])=C([H])C(=C([H])C=1[H])Br)OC1C([H])=C([H])C(=C([H])C=1[H])Br
|
| InChi Key |
LZDZRKDTUHPPOI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C36H24Br6N3O6P3/c37-25-1-13-31(14-2-25)46-52(47-32-15-3-26(38)4-16-32)43-53(48-33-17-5-27(39)6-18-33,49-34-19-7-28(40)8-20-34)45-54(44-52,50-35-21-9-29(41)10-22-35)51-36-23-11-30(42)12-24-36/h1-24H
|
| Chemical Name |
2,2,4,4,6,6-hexakis(4-bromophenoxy)-1,3,5-triaza-2λ5,4λ5,6λ5-triphosphacyclohexa-1,3,5-triene
|
| Synonyms |
Hexakis(p-bromophenoxy)cyclotriphosphazene; LUN76721; LUN-76721; LUN 76721;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.8569 mL | 4.2847 mL | 8.5694 mL | |
| 5 mM | 0.1714 mL | 0.8569 mL | 1.7139 mL | |
| 10 mM | 0.0857 mL | 0.4285 mL | 0.8569 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
